Palvella Therapeutics (NASDAQ:PVLA) Given Consensus Rating of “Buy” by Brokerages

Palvella Therapeutics (NASDAQ:PVLA) has received an average rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $43.20.

A number of research analysts have recently weighed in on the company. Scotiabank started coverage on Palvella Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price target on the stock. TD Cowen started coverage on shares of Palvella Therapeutics in a report on Wednesday, February 5th. They set a “buy” rating and a $44.00 price target for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $39.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They set an “overweight” rating on the stock. Finally, Jones Trading assumed coverage on Palvella Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $45.00 target price on the stock.

Palvella Therapeutics Trading Down 2.4 %

Shares of PVLA traded down $0.68 during midday trading on Tuesday, hitting $27.19. The stock had a trading volume of 28,214 shares, compared to its average volume of 61,300. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $29.27. The stock’s 50-day moving average price is $19.08. The company has a market capitalization of $305.10 million, a price-to-earnings ratio of -2.25 and a beta of 0.54.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Citadel Advisors LLC acquired a new position in shares of Palvella Therapeutics during the fourth quarter worth approximately $125,000. Toronto Dominion Bank bought a new stake in Palvella Therapeutics in the 4th quarter valued at $159,000. Geode Capital Management LLC acquired a new stake in Palvella Therapeutics in the 4th quarter worth $171,000. Cresset Asset Management LLC bought a new position in shares of Palvella Therapeutics during the 4th quarter worth about $251,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Palvella Therapeutics during the 4th quarter worth approximately $256,000. 40.11% of the stock is owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.